Cancers | Highly Viewed Papers and Hot Topic Special Issues in Lung Cancer

We are delighted to share a collection of highly viewed papers in lung cancer that were published in Cancers (ISSN: 2072-6694) in the first half of 2025. In addition, some Special Issues on this topic are currently open for submission. The following is a list of articles and Special Issues that we believe may be of interest to you:

The list of relevant papers can be seen below:

“AI-Driven Models for Diagnosing and Predicting Outcomes in Lung Cancer: A Systematic Review and Meta-Analysis”
by Mohammed Kanan, Hajar Alharbi, Nawaf Alotaibi, Lubna Almasuood, Shahad Aljoaid, Tuqa Alharbi, Leen Albraik, Wojod Alothman, Hadeel Aljohani, Aghnar Alzahrani et al.
Cancers 2025, 16(3), 674; https://doi.org/10.3390/cancers16030674
Available online: https://www.mdpi.com/2072-6694/16/3/674

“The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions”
by Angela Rina, Debora Maffeo, Francesca Minnai, Martina Esposito, Maria Palmieri, Viola Bianca Serio, Diletta Rosati, Francesca Mari, Elisa Frullanti and Francesca Colombo
Cancers 2025, 16(16), 2882; https://doi.org/10.3390/cancers16162882
Available online: https://www.mdpi.com/2072-6694/16/16/2882

“An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy”
by Saurav Verma, Daniel Breadner, Abhenil Mittal, David A. Palma, Rahul Nayak, Jacques Raphael and Mark Vincent
Cancers 2025, 16(7), 1302; https://doi.org/10.3390/cancers16071302
Available online: https://www.mdpi.com/2072-6694/16/7/1302

“Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients”
by Natalia Galant, Marcin Nicoś, Barbara Kuźnar-Kamińska and Paweł Krawczyk
Cancers 2025, 16(4), 782; https://doi.org/10.3390/cancers16040782
Available online: https://www.mdpi.com/2072-6694/16/4/782

“HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies”
by Giorgia Ferrari, Benedetta Del Rio, Silvia Novello and Francesco Passiglia
Cancers 2025, 16(11), 2018; https://doi.org/10.3390/cancers16112018
Available online: https://www.mdpi.com/2072-6694/16/11/2018

“ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer”
by Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, Marcelo Corassa, Philip C. Mack, Jhanelle E. Gray and Bruna Pellini
Cancers 2025, 16(5), 940; https://doi.org/10.3390/cancers16050940
Available online: https://www.mdpi.com/2072-6694/16/5/940

“Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer”
by Tianhong Li, Weijie Ma and Ebaa Al-Obeidi
Cancers 2025, 16(13), 2350; https://doi.org/10.3390/cancers16132350
Available online: https://www.mdpi.com/2072-6694/16/13/2350

“Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review”
by Filippo Lococo, Galal Ghaly, Marco Chiappetta, Sara Flamini, Jessica Evangelista, Emilio Bria, Alessio Stefani, Emanuele Vita, Antonella Martino, Luca Boldrini et al.
Cancers 2025, 16(10), 1832; https://doi.org/10.3390/cancers16101832
Available online: https://www.mdpi.com/2072-6694/16/10/1832

“Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies”
by Ahmed M. Mahmoud, Amr Moustafa, Carter Day, Mohamed E. Ahmed, Wael Zeina, Usama M. Marzouk, Spyridon Basourakos, Rimki Haloi, Mindie Mahon, Miguel Muniz et al.
Cancers 2025, 16(11), 2080; https://doi.org/10.3390/cancers16112080
Available online: https://www.mdpi.com/2072-6694/16/11/2080

“A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice”
by Hollis Viray, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi and Daniel B. Costa
Cancers 2025, 16(6), 1079; https://doi.org/10.3390/cancers16061079
Available online: https://www.mdpi.com/2072-6694/16/6/1079

Special Issues:

“New and Emerging Strategies for Targeting Genomic Instability and Overcoming Drug Resistance in Lung Cancer”
Guest Editor: Dr. Kelsie L. Thu
Submission deadline: 15 February 2026

“Advances in Lung Cancer Treatment Strategies”
Guest Editors: Dr. Alessandro Gonfiotti and Dr. Alice Ravasin
Submission deadline: 15 March 2026

“The EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs) and Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung Cancer”
Guest Editors: Dr. Greta Alì and Dr. Maria Giovanna Mastromarino
Submission deadline: 31 March 2026

“Clinical Pathology of Lung Cancer (2nd Edition)”
Guest Editor: Dr. Letizia Gnetti
Submission deadline: 30 June 2026

You can view and submit relevant papers to Cancers via the following link: https://www.mdpi.com/journal/cancers.

Cancers Editorial Office